The pharmaceutical industry environment is witnessing a significant transformation as key market participants channel substantial resources toward precision medicine, marking one of the most important advances in drug development in recent decades. This deliberate shift in focus reflects increasing awareness that conventional treatment approaches often overlook the distinct biological, environmental, and behavioral variables that influence individual therapeutic outcomes to pharmaceutical interventions. Major pharmaceutical firms are now investing billions in DNA analysis andREAD MORE
